LitAlert ~~ GeneLit.com

    • Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    • Cragun D, Weidner A, Tezak A, Clouse K, Pal T.
    • Breast Cancer Res Treat. 2020 May 22. doi: 10.1007/s10549-020-05699-y. [Epub ahead of print]
    • EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    • Lheureux S, Oaknin A, Garg S, Bruce JP, Madariaga A, Dhani NC, Bowering V, White J, Accardi S, Tan Q, Braunstein M, Karakasis K, Cirlan I, Pedersen S, Li T, Fariñas-Madrid L, Lee YC, Liu ZA, Pugh TJ, Oza AM.
    • Clin Cancer Res. 2020 May 22. pii: clincanres.4121.2019. doi: 10.1158/1078-0432.CCR-19-4121. [Epub ahead of print]
    • The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.
    • Gleeson M, Kentwell M, Meiser B, Do J, Nevin S, Taylor N, Barlow-Stewart K, Kirk J, James P, Scott CL, Williams R, Gamet K, Burke J, Murphy M, Antill YC, Pearn A, Pachter N, Ebzery C, Poplawski N, Friedlander M, Tucker KM, the Australian Genetic Testing Mainstreaming Collaborative Group.
    • Gynecol Oncol. 2020 May 22. pii: S0090-8258(20)31028-3. doi: 10.1016/j.ygyno.2020.05.001. [Epub ahead of print]
    • Mutation prevalence tables for hereditary cancer derived from multi-gene panel testing.
    • Hart SN, Polley EC, Yussuf A, Yadav S, Goldgar DE, Hu C, LaDuca H, Smith LP, Fujimoto J, Li S, Couch FJ, Dolinsky JS.
    • Hum Mutat. 2020 May 22. doi: 10.1002/humu.24053. Epub ahead of print.
    • Genetic Factors in the Locoregional Management of Breast Cancer.
    • Haffty BG, Euhus DM, Pierce LJ.
    • J Clin Oncol. 2020 May 22:JCO1902859. doi: 10.1200/JCO.19.02859. Epub ahead of print.
    • Review
    • Q&A: ACMG Work Group Hoping to Spark Discussion on Reporting Germline Findings From Tumor Testing.
    • Ray T.
    • Precision Oncology News. 2020 May 21.
    • News